UBS AM
VIR icon

UBS AM’s Vir Biotechnology VIR Stock Holding History

UBS AM’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Buy
164,147
+33,644
+26% +$320K ﹤0.01% 2134
2026
Q1 		$1.17M Buy
130,503
+9,423
+8% +$75.1K ﹤0.01% 2284
2025
Q4 		$730K Sell
121,080
-22,858
-16% -$136K ﹤0.01% 2239
2025
Q3 		$822K Sell
143,938
-150,445
-51% -$769K ﹤0.01% 2070
2025
Q2 		$1.48M Buy
294,383
+95,320
+48% +$511K ﹤0.01% 2275
2025
Q1 		$1.29M Buy
199,063
+17,738
+10% +$158K ﹤0.01% 2200
2024
Q4 		$1.33M Buy
181,325
+40,954
+29% +$323K ﹤0.01% 2234
2024
Q3 		$1.05M Sell
140,371
-30,188
-18% -$262K ﹤0.01% 2369
2024
Q2 		$1.52M Buy
170,559
+78,500
+85% +$753K ﹤0.01% 2143
2024
Q1 		$933K Hold
92,059
– – ﹤0.01% 2049
2023
Q4 		$926K Buy
92,059
+11,645
+14% +$106K ﹤0.01% 2064
2023
Q3 		$753K Sell
80,414
-8,829
-10% -$126K ﹤0.01% 2113
2023
Q2 		$2.08M Hold
89,243
– – ﹤0.01% 1626
2023
Q1 		$2.08M Buy
89,243
+17,498
+24% +$448K ﹤0.01% 1626
2022
Q4 		$1.82M Buy
71,745
+8,514
+13% +$209K ﹤0.01% 1568
2022
Q3 		$1.22M Sell
63,231
-15,335
-20% -$390K ﹤0.01% 1854
2022
Q2 		$2M Buy
78,566
+11,086
+16% +$259K ﹤0.01% 1612
2022
Q1 		$1.74M Buy
67,480
+2,438
+4% +$72.3K ﹤0.01% 1863
2021
Q4 		$2.72M Buy
65,042
+1,323
+2% +$51.8K ﹤0.01% 1724
2021
Q3 		$2.77M Buy
63,719
+549
+0.9% +$23.8K ﹤0.01% 1684
2021
Q2 		$2.99M Buy
63,170
+53,111
+528% +$2.41M ﹤0.01% 1664
2021
Q1 		$516K Hold
10,059
– – ﹤0.01% 2376
2020
Q4 		$269K Sell
10,059
-118,199
-92% -$3.84M ﹤0.01% 2434
2020
Q3 		$4.4M Sell
128,258
-21,599
-14% -$930K ﹤0.01% 1207
2020
Q2 		$6.14M Buy
+149,857
New +$5.03M ﹤0.01% 1045

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS AM's VIR Position: Q2 2026 in Review

UBS AM increased its Vir Biotechnology (VIR) stake by 26% in Q2 2026, buying an estimated $320K and bringing the position to 164,147 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

UBS AM first reported a position in VIR in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.14M in Q2 2020. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • UBS AM held 164,147 shares of Vir Biotechnology worth $1.67M as of Q2 2026.
  • UBS AM bought 33,644 Vir Biotechnology shares in Q2 2026, an estimated $320K.
  • Vir Biotechnology made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2134 holding.
  • UBS AM first reported a position in Vir Biotechnology in Q2 2020 and has held it in 25 quarters since.
  • UBS AM's Vir Biotechnology position peaked at $6.14M in Q2 2020.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.